Contraceptive Drugs Market Research Report: Information by Type [Oral Contraceptives (Combined Oral Contraceptive Pills and Progestogen-Only Pills), Topical Contraceptives, Contraceptive Injectables and others], Distribution Channel (Hospital & Clinics, Retail Pharmacy, Online Pharmacy and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027
ID: MRFR/Pharma/0768-HCR | February 2021 | Region: Global | 95 pages
Market Scenario
Contraceptive Drugs Market is expected to register 6.8% CAGR during the forecast period, 2019 to 2025, with a market value of USD 16790.02 Million in 2018.
Contraceptives drugs are used to prevent pregnancy and are one of the methods used to control birth. Oral contraceptives are hormonal preparations that may contain combinations of the hormone’s estrogen and progestin or progestin alone.
The global contraceptive drugs market is driven by factors such as the need to prevent the rising rate of unintended pregnancies and increasing awareness about contraceptive pills.
Additionally, the rise in government and NGO initiatives to promote contraceptive methods, easy use, and low costs of contraceptive drugs is anticipated to fuel the market growth.
For instance, according to the United Nations study ‘global perspectives on unplanned pregnancies’, globally, more than 41% of the 208 million pregnancies that occur each year are unplanned.
On the other hand, side effects associated with the use of contraceptive drugs is projected to hamper the growth of the market during the assessment period.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.
For instance, in April 2018, Mylan launched generic oral contraceptive Yaz tablets, which supported the company's growth in the global market.
Segmentation
The global contraceptive drugs market has been segmented into type, distribution channel, and region.
The global market, based on type, the market is further segmented into oral contraceptives, topical contraceptives, contraceptive injectable, and others.
The oral contraceptives segment is further bifurcated into combined oral contraceptive pills and progestogen-only pills. This segment is expected to hold a major share of the market due to easy consumption, over the counter availability of oral contraceptives, and low costs.
Based on distribution channel, the global market is segmented into hospital & clinics, retail pharmacy, online pharmacy, and others.
The retail pharmacy segment is anticipated to be the fastest-growing segment due to the increasing over the counter purchase of contraceptive drugs.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The contraceptive drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European contraceptive drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The contraceptive drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The contraceptive drugs market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The Key Players in the Global Contraceptive Drugs Market are Bayer AG (Germany), Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), Mylan N.V.(US), Allergan Plc (Ireland), Agile Therapeutics (US), Piramal Enterprises Ltd. (India), GlaxoSmithKline PLC (UK), Johnson & Johnson (US), Novartis AG (Europe), and Sanofi (France).
Regional Market Summary
Global Contraceptive Drugs Market Share by Region, 2018 (%)
Source: World Health Organization (WHO)
The market in the Americas is expected to dominate the global contraceptive drugs market due to the growing rate of unintended pregnancies and the need to prevent abortions in the region. Growing awareness about contraception in the US and Canada is expected to drive the market growth.
For example, according to an article by the National Center for Biotechnology Information, published in 2017, in the US, 45% of pregnancies are estimated to be unintended each year. Thus, to avoid abortions due to unwanted pregnancies, the use of contraceptive drugs is increasing.
The market in Asia-Pacific is expected to show a considerable amount of growth during the forecast period owing to the growing awareness about contraceptive pills and increasing government initiatives to promote contraceptive methods.
For example, in 2017, the Ministry of Health and Family Welfare of India launched two new contraceptives, a contraceptive pill ‘Chhaya’ and an injectable contraceptive MPA under the ‘Antara’ program.
The market in Europe is expected to show a considerable amount of growth, owing to the increasing number of unintended pregnancies.
The market in the Middle East & Africa is projected to account for the least share of the market due to less awareness about contraceptive drugs in the region.
Global Contraceptive Drugs Market, by Type
- Oral Contraceptives
- Combined Oral Contraceptive Pills
- Progestogen-Only Pills
- Topical Contraceptives
- Contraceptive Injectable
- Others
Global Contraceptive Drugs Market, by Distribution Channel
- Hospital & Clinics
- Retail Pharmacy
- Online Pharmacy
- Others
Global Contraceptive Drugs Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Research and development (R&D) companies
- Pharmaceutical & biotechnology companies
- Government research institutes
- Academic institutes and universities
- Venture capitalists
Frequently Asked Questions (FAQ) :
Contraceptive Drugs Market is predicted CAGR would be 6.8%.
The valuation was USD 16790.02 million.
The retail pharmacy segment would lead the market.
The oral contraceptives segment to lead the Contraceptive Drug Market.
The Americas have a maximum Contraceptive Drug Market.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Overview
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Contraceptive Drugs Market, by Type
6.1 Overview
6.2 Oral Contraceptives
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.1 Combined Oral Contraceptive Pills
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2 Progestogen-Only Pills
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3 Topical Contraceptives
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4 Contraceptive Injectable
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 7 Global Contraceptive Drugs Market, by Distribution Channel
7.1 Overview
7.2 Hospital & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3 Retail Pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4 Online Pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 10. Global Contraceptive Drugs Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Overview
11.2 Competitive Analysis
Chapter 12. Company Profile
12.1 Bayer AG
12.1.1 Company Overview
12.1.2 Product Type Overview
12.1.3 Financial Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Pfizer Inc.
12.2.1 Company Overview
12.2.2 Product Type Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Teva Pharmaceutical Industries Ltd.
12.3.1 Company Overview
12.3.2 Product Type Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Merck & Co., Inc.
12.4.1 Company Overview
12.4.2 Product Type Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Mylan N.V.
12.5.1 Company Overview
12.5.2 Product Type Overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Allergan Plc
12.6.1 Company Overview
12.6.2 Product Type Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Agile Therapeutics
12.7.1 Overview
12.7.2 Product Type Overview
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Piramal Enterprises Ltd.
12.8.1 Overview
12.8.2 Product Type Overview
12.8.3 Financial Overview
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 GlaxoSmithKline PLC
12.9.1 Overview
12.9.2 Product Type Overview
12.9.3 Financial Overview
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Johnson & Johnson
12.10.1 Overview
12.10.2 Product Type Overview
12.10.3 Financial Overview
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Novartis AG
12.11.1 Overview
12.11.2 Product Type Overview
12.11.3 Financial Overview
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.12 Sanofi
12.12.1 Overview
12.12.2 Product Type Overview
12.12.3 Financial Overview
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.13 Others
Chapter 13 Appendix
13.1 References
13.2 Related Reports
LIST OF TABLES
Table 1 Global Contraceptive Drugs Market Synopsis, 2020-2027
Table 2 Global Contraceptive Drugs Market Estimates and Forecast, 2020-2027 (USD Million)
Table 3 Global Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 4 Global Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 5 Global Contraceptive Drugs Market, by Region, 2020-2027 (USD Million)
Table 6 North America: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 7 North America: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 8 US: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 9 US: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 10 Canada: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 11 Canada: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 12 Latin America: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 13 Latin America: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 14 Europe: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 15 Europe: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 16 Western Europe: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 17 Western Europe: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 18 Eastern Europe: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 19 Eastern Europe: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 20 Asia-Pacific: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 21 Asia-Pacific: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Table 22 Middle East & Africa: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Table 23 Middle East & Africa: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure of the Global Contraceptive Drugs Market
Figure 3 Market Dynamics of the Global Contraceptive Drugs Market
Figure 4 Global Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)
Figure 5 Global Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)
Figure 6 Global Contraceptive Drugs Market, by Region, 2020-2027 (USD Million)
Figure 9 North America: Contraceptive Drugs Market Share, by Country, 2020 (%)
Figure 7 Europe: Contraceptive Drugs Market Share, by Region, 2020 (%)
Figure 8 Western Europe: Contraceptive Drugs Market Share, by Country, 2020 (%)
Figure 9 Asia-Pacific: Contraceptive Drugs Market Share, by Country, 2020 (%)
Figure 10 Middle East & Africa: Contraceptive Drugs Market Share, by Country, 2020 (%)
Figure 11 Global Contraceptive Drugs Market: Company Share Analysis, 2020 (%)
Figure 12 Bayer AG: Key Financials
Figure 13 Bayer AG: Segmental Revenue
Figure 14 Bayer AG: Regional Revenue
Figure 15 Pfizer Inc.: Key Financials
Figure 16 Pfizer Inc.: Segmental Revenue
Figure 17 Pfizer Inc.: Regional Revenue
Figure 18 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 19 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 20 Teva Pharmaceutical Industries Ltd.: Regional Revenue
Figure 21 Merck & Co., Inc.: Key Financials
Figure 22 Merck & Co., Inc.: Segmental Revenue
Figure 23 Merck & Co., Inc.: Regional Revenue
Figure 27 Mylan N.V.: Key Financials
Figure 28 Mylan N.V.: Segmental Revenue
Figure 29 Mylan N.V.: Regional Revenue
Figure 30 Allergan Plc: Key Financials
Figure 31 Allergan Plc: Segmental Revenue
Figure 32 Allergan Plc: Regional Revenue
Figure 33 Agile Therapeutics: Key Financials
Figure 34 Agile Therapeutics: Segmental Revenue
Figure 35 Agile Therapeutics: Regional Revenue
Figure 36 Piramal Enterprises Ltd.: Key Financials
Figure 37 Piramal Enterprises Ltd.: Segmental Revenue
Figure 38 Piramal Enterprises Ltd.: Regional Revenue
Figure 39 GlaxoSmithKline PLC: Key Financials
Figure 40 GlaxoSmithKline PLC: Segmental Revenue
Figure 41 GlaxoSmithKline PLC: Regional Revenue
Figure 42 Johnson & Johnson: Key Financials
Figure 43 Johnson & Johnson: Segmental Revenue
Figure 44 Johnson & Johnson: Regional Revenue
Figure 45 Novartis AG: Key Financials
Figure 46 Novartis AG: Segmental Revenue
Figure 47 Novartis AG: Regional Revenue
Figure 48 Sanofi: Key Financials
Figure 49 Sanofi: Segmental Revenue
Figure 50 Sanofi: Regional Revenue
